Precision BioSciences(DTIL) - 2025 Q4 - Annual Results

Financial Outlook - As of December 31, 2025, Precision BioSciences expects to report approximately $137 million in cash, cash equivalents, and restricted cash[8] - The company anticipates that its cash runway will extend through 2028, supported by existing cash, potential near-term licensee considerations, and fiscal discipline[9] Clinical Trials - Additional biopsy data from the ELIMINATE-B trial for PBGENE-HBV is expected in the first half of 2026[12] - The FUNCTION-DMD Phase 1/2 clinical trial in Duchenne muscular dystrophy patients is expected to dose the first patient in late Q1 or early Q2 2026, with initial data anticipated by year-end 2026[13] Strategic Priorities - The company has set strategic priorities for 2026, as announced in a press release on January 12, 2026[10]